Phase 3 Trials Will Test Self-injectable Crovalimab

Phase 3 Trials Will Test Self-injectable Crovalimab

300093

Phase 3 Trials Will Test Self-injectable Crovalimab

Two Phase 3 clinical trials will evaluate the safety and effectiveness of Roche’s investigational, self-injectable therapy crovalimab (RG6107) in children, adolescents, and adults with atypical hemolytic uremic syndrome (aHUS). The first trial, called COMMUTE-a (NCT04861259), already is recruiting aHUS patients, ages 12 and older, at sites in the U.S. and Japan, with sites in 15 other countries expected to soon open. More information about contacts and locations are available here. The second study, called COMMUTE-p (NCT04958265) and…

You must be logged in to read/download the full post.